NightstaRx Archives

In Depth 11 Jun 2025

Can gene therapy treat vision loss?

Since the approval of Luxturna, there has been a wave of companies developing treatments with the potential to cure different forms of genetic blindness.

June 11, 2025 - 12 minutesmins - By Roohi Mariam Peter

biogen nightstar therapeutics gene therapy ophthalmology

News and Trends 4 Mar 2019

Biogen Acquires UK Biotech Developing Gene Therapy for Blindness

The big US biotech Biogen has agreed to acquire Nightstar Therapeutics for €773M ($877M), including Nightstar’s candidate gene therapies for inherited blindness. Expected to be complete by mid-2019, Biogen’s acquisition of Nightstar bags it the UK company’s most advanced program. Currently in phase III, the therapy targets choroidemia, an incurable genetic condition which causes progressive […]

March 4, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 24 Sep 2018

Gene Therapy Improves Eyesight of Patients With Inherited Blindness

UK startup Nightstar Therapeutics has reported good safety and early signs of visual improvements in a Phase I/II trial with a gene therapy for a rare form of inherited blindness. One month after being treated with Nightstar’s gene therapy, five of the 18 patients enrolled in the trial have already shown improvements in their vision. […]

September 24, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 6 Mar 2018

Oxford Spin-out Moves Gene Therapy For Blindness Into Phase III Trial

Nightstar Therapeutics will begin the first Phase III trial for a gene therapy targeting choroideremia, a rare disorder leading to complete blindness. Nightstar will launch the first-ever Phase III trial testing a gene therapy for choroideremia, a genetic disorder characterized by night blindness and gradual loss of vision that eventually leads to complete blindness. The trial, STAR, […]

March 6, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 28 Sep 2017

Oxford Spinout goes for $75M IPO on Nasdaq to Fund Gene Therapy Programs

Nightstar has gone public on the American market with the aim of raising $75M for its gene-based retinal disease cures. Spun out from Oxford in 2013, Nightstar is developing and commercializing one-shot gene therapies for various eye diseases that could lead to blindness. This morning, it debuted on the Nasdaq with a projected $75M (£56M / €64M) […]

September 28, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 30 Jun 2017

€40M in Series C for a British Biotech Treating Blindness with Gene Therapy

NightstaRx has raised €39.5M that will go towards three clinical programs testing gene therapies for rare diseases that cause blindness. NightstaRx is developing gene therapies for genetic retinal diseases that cause blindness, with technology from the University of Oxford. Now getting closer to the market, the company has closed a Series C round with $45M (€39.5M) […]

June 30, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 11 Nov 2015

Oxford’s Nightstar Gene Therapy for Blindness in Men Shines with $35M Fundraiser

Choroideremia is a rare X-linked recessive retinal disease which eventually leads to blindness. A series B funding round has landed the NightstaRx (‘Nightstar’) biotech in Oxford an additional $35M for their vision-improving gene therapy. Since the mutation causing Choroideremia is sex-linked, sufferers are almost always males, with the onset of symptoms in childhood often starting […]

November 11, 2015 - 3 minutesmins - By Dani Bancroft

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

NightstaRx

Can gene therapy treat vision loss?

Biogen Acquires UK Biotech Developing Gene Therapy for Blindness

Gene Therapy Improves Eyesight of Patients With Inherited Blindness

Oxford Spin-out Moves Gene Therapy For Blindness Into Phase III Trial

Oxford Spinout goes for $75M IPO on Nasdaq to Fund Gene Therapy Programs

€40M in Series C for a British Biotech Treating Blindness with Gene Therapy

Oxford’s Nightstar Gene Therapy for Blindness in Men Shines with $35M Fundraiser

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!